Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL)

American Journal of Hematology

Volumn 78, Issue 3, 2005, Pages 173-180

  Nakagawa, Yasunori ^a,b   Hasegawa, Maki ^a   Kurata, Morito ^a   Yamamoto, Kouhei ^a   Abe, Shinya ^a   Inoue, Miori ^a   Takemura, Tamiko ^b   Hirokawa, Katsuiku ^a   Suzuki, Kenshi ^b   Kitagawa, Masanobu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

ALL; AML; AMLL; Apoptosis; Bone marrow; IAP

Indexed keywords

CD79A ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENOCITABINE; ETOPOSIDE; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN NAIP; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MYELOPEROXIDASE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SURVIVIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL LEVEL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MALE; MIXED LINEAGE LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MIXED-CELL; LEUKEMIA, MONOCYTIC, ACUTE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 20044362738     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20285     Document Type: Article

References (42)

1. Pileri SA, Ascani S, Milani M, et al. Acute leukemia immunophenotyping in bone-marrow routine sections. Br J Haematol 1999;105:394-401.
2. Matutes E, Morilla R, Farahat N, et al. Definition of acute biphenotypic leukemia. Haematologica 1997;82:64-66.
3. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplication of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002;20:3254-3261.
4. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-47.
5. Kofler R, Schmidt S, Kofler A, Ausserlechner MJ. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 2003;178:19-27.
6. Stam RW, den Boer ML, Meijerink JPP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270-1276.
7. Kitagawa M, Kamiyama R, Kasuga T. Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. Hum Pathol 1993;24:359-363.
8. Kitagawa M, Yoshida S, Kuwata T, Tanizawa T, Kamiyama R. p53 expression in myelodysplastic syndromes: association with evolution of overt leukemia. Am J Pathol 1994;145:338-344.
9. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-α and Interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049-2054.
10. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998;12:486-492.
11. Kitagawa M, Takahashi M, Yamaguchi S, et al. Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. Leukemia 1999;13:699-703.
12. Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow form patients with myelodysplastic syndromes. Leukemia Res 2003;27:583-591.
13. Nakagawa Y, Yamaguchi S, Hasegawa M, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leukemia Res 2004;28:487-494.
14. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-3259.
15. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-5320.
16. Shin S, Sung B-J, Cho Y-S, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40:1117-1123.
17. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
18. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptotic gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-49.
19. Velculescu VE, Madden S, Zhang L, et al. Analysis of human transcriptomes. Analysis of human transcriptomes. Nat Genet 1999;23:387-388.
20. Altieri DC, Marchisio C. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 1999;79:1327-1333.
21. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001;32:119-125.
22. Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001;91:2026-2032.
23. Okada E, Murai Y, Matsui K, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001;163:109-116.
24. Rodriguez JA, Span SW, Ferreira CGM, Kruyt FAE, Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res 2002;275:44-53.
25. Yamamoto K, Abe S, Nakagawa Y, et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leukemia Res 2004;28(11):1203-1211.
26. Rothe M, Pan MG, Henzei WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995;83:1243-1252.
27. Duckett CS, Nava VE, Gedrich RW, et al. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J 1996;15:2685-2694.
28. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996;379:349-353.
29. Roy N, Dereraux QL, Takahashi R, Salvesen GS, Reed JC. The cIAP-1 and cIAP-2 proteins are distinct inhibitors of specific caspases. EMBO J 1997;16:6914-6925.
30. Delacretaz F, Schmidt P-M, Piguet D, Bachmann F, Costa J. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 1987;87:180-186.
31. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
32. Strout MP, Marcucci G, Caligiuri MA, Bloomfield CD. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: Biology and clinical implications. Ann Hematol 1999;78:251-264.
33. Armstrong JA, Golub TR, Korsmeyer SJ. MLL-rearranged leukemias: insights from gene expressing profiling. Semin Hematol 2003;40:268-273.
34. Moriai R, Asanuma K, Kobayashi D, et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res 2001;21:595-600.
35. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukemia. Br J Haematol 2000;111:196-203.
36. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-2783.
37. Vogel LA, Noelle RJ. CD40 and its crucial role as a member of the TNFR family. Semin Immunol 1998;10:435-442.
38. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992;80:3173-3181.
39. Hirose M, Hosoi E, Hamano S, Jalili A. Multidrug resistance in hematological malignancy. J Med Invest 2003;50:26-35.
40. Legrand O, Perrot J-Y, Simonin G, et al. Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavorable cytogenetics and P-glycoprotein over-expression. Br J Haematol 1998;100:147-155.
41. Killick S, Matutes E, Powles RL, et al. Outcome of biphenotypic acute leukemia. Haematologica 1999;84:699-706.
42. Schraets D, Lehmann T, Dingermann T, Marschalek R. MLL-mediated transcriptional gene regulation investigated by gene expression profiling. Oncogene 2003;22:3655-3668.